Latest Cash Management News

Amara Minerals has warned of a material uncertainty over its ability to continue as a going concern after reporting an $8.79 million FY2026 loss and $2.08 million in cash. The company is advancing Victorian gold-antimony exploration, but further equity funding is required and a GST-related court dispute remains unresolved.

TradeWindow is targeting 13% to 18% revenue growth in FY27 and expects to approach EBITDA breakeven, while preparing to shift its primary listing from the NZX to the ASX. The freight software company also reported rising recurring revenue, stronger customer economics and NZ$4.0 million in cash at 30 June 2026.

Far Northern Resources expanded its Northern Territory gold inventory to 117,000 ounces during FY26, while Bridge Creek moved closer to mining studies. The progress came alongside a wider annual loss, falling cash reserves and an auditor-emphasised going-concern consideration.

Perpetual Diversified Income Fund lifted operating profit 38% to $169.9 million and grew net assets to $3.255 billion in the year to 30 June 2026. The fund also launched its Class E Active ETF, ASX:DIFF, while KPMG issued an unqualified audit opinion.

Li-S Energy says its Geelong lithium-sulfur production line is complete and has delivered 10Ah Power Cells to the US Army for testing. The company is targeting its first commercial battery sale in 2027, while holding A$15.6 million in cash and investments and A$9.3 million in secured grants yet to be received.

Blackpearl Group more than doubled annual recurring revenue to NZ$26.8 million in FY26, but the growth came alongside an NZ$17.8 million loss and a formal material uncertainty over its ability to continue as a going concern. The company says cost reductions, faster cash conversion and its refinanced BNZ facility can support the next phase.

Fitzroy River Corporation reported a modest loss for FY26, with a key highlight being a $12.27 million disputed payment from Endura Mining related to its Snowy River Gold Project royalty. The company has initiated court proceedings in New Zealand to clarify the validity of this buyout option while exploring potential sale of its Bowdens Silver royalty.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

Talius Group’s HY2026 results reveal a strategic pivot towards higher-margin software subscriptions, with gross margin surging to 51% despite a 19% revenue dip due to hardware deployment timing. Active subscriptions topped 53,200, underpinning a $3.26 million ARR, while cash burn shrank dramatically.

Summerset Group Holdings posted a 92% jump in half-year net profit to NZ$171.4 million, driven by strong sales and disciplined cash management. The company also updated its dividend policy to align payouts with operating cash flow, reflecting its maturing portfolio and cautious growth approach.

Xenitra Limited has secured A$1.5 million through a discounted share placement to accelerate growth in higher-margin OTC medicines, FSMP, and tokenised FMCG sales. The capital will fund inventory expansion, supplier fulfilment, and ecommerce activation as the company shifts from low-margin distribution to a diversified healthcare platform.

Cyclopharm Limited posted a fifth consecutive record half-year revenue of $17.5 million, propelled by a 74% jump in US Technegas® sales and a doubling of revenue-generating US sites. New US clinical guidelines naming Technegas® as the preferred ventilation imaging agent underpin a robust growth outlook despite a wider net loss.